April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
The relationship between frequency doubling technology (FDT) perimetry and useful field of view (UFOV) testing in glaucoma
Arielle R Spitze; Andrew J Tatham; Peter Rosen; Linda M Zangwill; Robert N Weinreb; Michelle A Sato; Erwin R Boer; Felipe A Medeiros
Author Affiliations & Notes
  • Arielle R Spitze
    Hamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, La Jolla, CA
  • Andrew J Tatham
    Hamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, La Jolla, CA
  • Peter Rosen
    Hamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, La Jolla, CA
  • Linda M Zangwill
    Hamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, La Jolla, CA
  • Robert N Weinreb
    Hamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, La Jolla, CA
  • Michelle A Sato
    Hamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, La Jolla, CA
  • Erwin R Boer
    Hamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, La Jolla, CA
  • Felipe A Medeiros
    Hamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, La Jolla, CA
  • Footnotes
    Commercial Relationships Arielle Spitze, None; Andrew Tatham, Heidelberg Engineering (F); Peter Rosen, None; Linda Zangwill, Carl Zeiss Meditec Inc (F), Heidelberg Engineering Inc (F), Nidek Inc (F), Optovue Inc (F), Topcon Medical Systems Inc (F); Robert Weinreb, Aerie (F), Alcon (C), Allergan (C), Bausch & Lomb (C), Carl Zeiss Meditec (C), Carl Zeiss Meditec (F), Genentech (F), Heidelberg Engineering, Inc. (F), National Eye Institute (F), Nidek (F), Optovue (F), Sensimed (C), Topcon, Inc. (C), Topcon, Inc. (F); Michelle Sato, None; Erwin Boer, None; Felipe Medeiros, Alcon Laboratories, Inc. (F), Alcon Laboratories, Inc. (R), Allergan, Inc. (C), Allergan, Inc. (F), Allergan, Inc. (R), Bausch & Lomb (F), Carl-Zeiss Meditec, Inc. (C), Carl-Zeiss Meditec, Inc. (F), Carl-Zeiss Meditec, Inc. (R), Heidelberg Engineering, Inc. (F), Merck, Inc. (F), National Eye Institute (F), Novartis (C), Reichert, Inc. (F), Reichert, Inc. (R), Sensimed (F), Topcon, Inc. (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 5648. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      The relationship between frequency doubling technology (FDT) perimetry and useful field of view (UFOV) testing in glaucoma
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      Arielle R Spitze, Andrew J Tatham, Peter Rosen, Linda M Zangwill, Robert N Weinreb, Michelle A Sato, Erwin R Boer, Felipe A Medeiros; The relationship between frequency doubling technology (FDT) perimetry and useful field of view (UFOV) testing in glaucoma. Invest. Ophthalmol. Vis. Sci. 2014;55(13):5648.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: Frequency doubling technology (FDT) has been proposed as a perimetric test for the diagnosis of glaucoma, targeting the magnocellular pathway. This pathway is thought to process information about the location and movement of objects and also to be associated with spatial attention processing. The Useful Field of View (UFOV) is a binocular test able to assess processing speed under a divided attention task, which has been shown to be predictive of driving ability in older adults. The purpose of this study was to evaluate the ability of FDT to predict UFOV results and to compare it to that of conventional standard automated perimetry (SAP).

Methods: This was a cross-sectional study including both eyes of 75 subjects with glaucoma, 181 subjects suspected of having glaucoma, and 57 healthy subjects. All subjects were recruited from the Diagnostic Innovations in Glaucoma Study (DIGS). All subjects had Matrix FDT, SAP, and UFOV testing within 3 months. Glaucoma was defined based on the presence of glaucomatous optic neuropathy on masked assessment of stereophotographs. The relationships between UFOV results (log of divided attention time) and mean sensitivities (in decibels) for FDT and SAP were examined with linear regression models adjusting for age.

Results: The mean age of included subjects was 60 ± 16 years. Mean FDT sensitivity values in the better eye were 23.8 ± 3.8 dB, 26.2 ± 4.0 dB, and 28.3 ± 2.8 dB in glaucoma, suspects, and healthy subjects, respectively. Corresponding values for SAP were 28.5 ± 2.1 dB, 30 ± 2.3 dB and 31.4 ± 1.1 dB, respectively. Lower sensitivity values for the better eye on FDT perimetry were significantly associated with slower UFOV divided attention results (P<0.001). However, the ability of FDT perimetry to predict UFOV results was not significantly different than that of SAP (adjusted R2 of 19% and 22%, respectively, for multivariable models adjusting for age). Similar results were obtained when the worse eye was considered.

Conclusions: There was a statistically significant relationship between FDT results and UFOV measurements of processing speed under divided attention. However, the ability of FDT perimetry to predict UFOV results was not significantly better than that of conventional SAP.

Keywords: 758 visual fields • 414 aging: visual performance • 549 image processing  
© 2014, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2024 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept